Online inquiry

IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3084MR)

This product GTTS-WQ3084MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FASLG gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 356
UniProt ID Q53ZZ1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3084MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7641MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ9762MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ4785MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ13933MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ8100MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ3097MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ8392MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HS006
GTTS-WQ15602MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VAL-1221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW